Tevogen Bio Holdings Inc. has expanded its relationship with Microsoft Corp. to broaden their AI-focused collaboration and build its Predictcell technology for predictive precision T-cell targeting.

Immvention Therapeutix Inc. has entered into a collaboration and license agreement with Novo Nordisk A/S to co-develop oral therapies for sickle cell disease and other chronic conditions.

Immuron Ltd. has signed a new research collaboration agreement with Monash University to develop new therapeutic drug candidates targeting antimicrobial-resistant pathogens. This work will utilize the Immuron technology platform, and the experience of the Biomedicine Discovery Institute research team.

Anges Inc. has entered into a sponsored research agreement with Stanford University School of Medicine for the development of novel cancer therapies using genome editing technology. The parties aim to combine nucleic acid drug delivery technology developed at Stanford with the genome editing technology of Emendobio Inc., a subsidiary of Anges.

Zai Lab Ltd. has entered into a new strategic collaboration and worldwide license agreement with Medilink Therapeutics (Suzhou) Co. Ltd. to use Medilink’s TMALIN antibody-drug conjugate (ADC) platform.

Institut Pasteur Korea has signed a memorandum of understanding (MOU) with four Pohang University of Science and Technology (POSTECH)-affiliated research institutes with the aim of pursuing joint research on mRNA vaccine and treatment development.

Amylyx Pharmaceuticals Inc. and Gubra A/S have established a collaboration for the development of a novel long-acting GLP-1 receptor antagonist.

Hangzhou Sino-US Huadong Medicine Co. Ltd. and Synerk Pharmatech (Suzhou) Co. Ltd. have entered into a strategic collaboration in which the two parties will jointly develop the small nucleic acid (siRNA) drug SNK-2726.

Gilead Sciences Inc. and Terray Therapeutics Inc. have entered into a strategic collaboration to discover and develop novel small-molecule therapies across multiple targets.